title: Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
abstract: OBJECTIVE
  To evaluate the functional abilities and the level of ambulation during pamidronate therapy in children with moderate to severe osteogenesis imperfecta.
  
  
  METHODS
  Functional abilities, ambulation, and grip force were assessed in 59 patients (mean age, 6.1 years; range, 0.5-15.7 years; 30 girls) during 3 years of pamidronate treatment. Functional skills (mobility and self-care) were both assessed by using the Pediatric Evaluation of Disability Inventory. Ambulation level was assessed by using the modified Bleck score. For 48 patients, results after 3 years of pamidronate treatment could be matched to those of patients with similar age and disease severity who had not received pamidronate.
  
  
  RESULTS
  Mobility and self-care scores increased during the study period (+43% and +30%, respectively). The average ambulation score changed from 0.8 to 1.9. Maximal isometric grip force increased by 63%. Mobility and ambulation scores and grip force measures were significantly higher than in patients who had not received pamidronate. The difference in self-care scores did not reach significance.
  
  
  CONCLUSIONS
  This study suggests that cyclical pamidronate treatment improves mobility, ambulation level, and muscle force in children with moderate to severe osteogenesis imperfecta.
authors.affiliation: Genetics Unit, Shriners Hospital for Children and McGill University, Montréal, Québec, Canada.
authors.forename: Christof
authors.initials: C
authors.lastname: Land
authors.forename: Frank
authors.initials: F
authors.lastname: Rauch
authors.forename: Kathleen
authors.initials: K
authors.lastname: Montpetit
authors.forename: Joanne
authors.initials: J
authors.lastname: Ruck-Gibis
authors.forename: Francis H
authors.initials: FH
authors.lastname: Glorieux
mesh_terms: D000203:Activities of Daily Living; D000293:Adolescent; D000704:Analysis of Variance; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D010013:Osteogenesis Imperfecta / Q000188:drug therapy* / Q000534:rehabilitation; D000077268:Pamidronate; D012648:Self Care; D016138:Walking
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate